Trial Profile
A Phase 2, Multicentre, Single Arm, Pilot Study to Assess the Efficacy and the Safety of 150 mg Twice a Day Oral DF2156A in Patients With Active Bullous Pemphigoid
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 30 Sep 2022
Price :
$35
*
At a glance
- Drugs Ladarixin (Primary)
- Indications Bullous pemphigoid
- Focus Adverse reactions; Therapeutic Use
- Sponsors Dompe Farmaceutici; Dompe Spa
- 22 May 2014 New trial record